GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: XL01126 is a VHL-based PROTAC degrader targeting leucine rich repeat kinase 2 (LRRK2). The LRRK2 binding moeity of the compound is the brain-penetrant kinase inhibitor HG-10-102-01. XL01126 is orally bioavailable and retains the ability of the parent kinase inhibitor to cross the blood-brain barrier. LRRK2 is an active therapeutic target for Parkinson's disease, since activating coding mutations in LRRK2 are associated with dominantly inherited Parkinson's disease [1-2,5]. XL01126's development was led by Dundee University's Centre for Targeted Protein Degradation and the Research Institute for Medicines at the University of Lisbon. Initially disclosed in a ChemRxiv preprint [4].  Cereblon-targeting LRRK2 PROTACs have been disclosed previously, but these were found to be inefficient target degraders [3]. | 
 | |||||||||||||||||||||||||||||||||||
| Classification  | |
| Compound class | Synthetic organic | 
| Ligand families/groups | PROTACs, molecular glues and other degraders | 
| Database Links  | |
| GtoPdb PubChem SID | 464244150 | 
| PubChem CID | 163358787 | 
| Search Google for chemical match using the InChIKey | XSOATTNBVDAEAR-QGHWPEOCSA-N | 
| Search Google for chemicals with the same backbone | XSOATTNBVDAEAR | 
| UniChem Compound Search for chemical match using the InChIKey | XSOATTNBVDAEAR-QGHWPEOCSA-N | 
| UniChem Connectivity Search for chemical match using the InChIKey | XSOATTNBVDAEAR-QGHWPEOCSA-N |